Ivabradine Auxilto

Ivabradine, the active ingredient in Ivabradine Auxilto, is an If channel inhibitor presented as an oral tablet for oral use. It selectively lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients who require heart‑rate control and have been evaluated for suitability.

GNH USA supplies Ivabradine Auxilto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions.

Ivabradine acts on the cardiac If channel to reduce heart rate, benefiting specific cardiovascular conditions.

- Chronic stable angina: decreases the frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate to improve ventricular filling and reduce risk of hospitalization. - Patients intolerant to beta‑blockers: provides heart‑rate reduction without affecting myocardial contractility.

Adverse reactions may occur with ivabradine therapy. Patients should be monitored for any new symptoms.

Common Side Effects: - Phosphenes (transient visual disturbances) - Bradycardia - Headache - Dizziness - Fatigue - Blurred vision

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical intervention - Atrial fibrillation or other arrhythmias - Severe hypotension - Visual loss or retinal abnormalities - QT interval prolongation - Allergic skin reactions

Ivabradine requires careful patient assessment and monitoring. - Baseline heart rate assessment: ensure resting heart rate is ≥70 bpm before initiation. - Contraindicated in severe hepatic impairment: avoid use in patients with Child‑Pugh C liver disease. - Caution in sick sinus syndrome: monitor for excessive bradycardia. - Avoid concomitant strong CYP3A4 inhibitors: may increase plasma concentrations. - Store at below 25°C: keep in the original pack, protect from moisture.

Ivabradine may interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase ivabradine levels. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive heart‑rate reduction. - Other If channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may require dose adjustment. - Antihypertensive agents: monitor blood pressure and heart rate. - Diuretics: watch for electrolyte disturbances that could affect cardiac conduction.